China-based Duality Biotherapeutics' (HKEX:09606) partner, Avenzo Therapeutics, Inc., a California-based clinical-stage biotechnology company developing next-generation oncology therapies, announced on Tuesday that the first patient has been dosed in the Phase 1 portion of a Phase 1/2 clinical study evaluating AVZO-1418/DB-1418.
AVZO-1418/DB-1418 is a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumours.
On January 7, 2025, DualityBio and Avenzo announced that they had entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture, and commercialise AVZO-1418/DB-1418 globally (excluding Greater China).
The Phase 1/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-1418/DB-1418 as a single agent and in combination therapy in patients with advanced solid tumours.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval